Stanislav Glezer
Chief Tech/Sci/R&D Officer chez INOGEN, INC.
Fortune : 129 975 $ au 31/03/2024
Profil
Le Dr Stanislav Glezer est directeur médical et vice-président exécutif d'Inogen, Inc. et vice-président mondial des affaires médicales de Becton, Dickinson & Co. Il siège au conseil d'administration de la Diabetes Foundation of New Jersey. Auparavant, le Dr Glezer a occupé le poste de directeur médical chez Adocia SA et celui de vice-président des affaires médicales mondiales chez Novo Nordisk, Inc. Il a obtenu un MBA de la California Coast University et un doctorat du Yevdokimov MSUMD.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INOGEN, INC.
0,07% | 01/03/2024 | 16 106 ( 0,07% ) | 129 975 $ | 31/03/2024 |
Postes actifs de Stanislav Glezer
| Sociétés | Poste | Début |
|---|---|---|
| INOGEN, INC. | Chief Tech/Sci/R&D Officer | 21/06/2021 |
| Diabetes Foundation of New Jersey | Director/Board Member | 24/07/2019 |
Anciens postes connus de Stanislav Glezer
| Sociétés | Poste | Fin |
|---|---|---|
| BECTON, DICKINSON AND COMPANY | Chief Tech/Sci/R&D Officer | 01/06/2021 |
| ADOCIA | Chief Tech/Sci/R&D Officer | 01/05/2018 |
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Chief Tech/Sci/R&D Officer | 01/03/2017 |
| Sanofi SA | Corporate Officer/Principal | - |
Formation de Stanislav Glezer
| California Coast University | Masters Business Admin |
| Yevdokimov MSUMD | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BECTON, DICKINSON AND COMPANY | Health Technology |
| INOGEN, INC. | Health Technology |
| ADOCIA | Health Technology |
| Entreprise privées | 3 |
|---|---|
Novo Nordisk, Inc.
Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Health Technology |
| Sanofi SA | Health Technology |
| Diabetes Foundation of New Jersey |
